S&P 500 hits another record | Inflation higher, but not as bad as feared | J&J vaccine pause

U.S. stocks traded mostly higher on Tuesday after a March inflation report turned out not as bad as some traders feared, but the impact of a halt to the rollout of Johnson & Johnson vaccine kept optimism in check.

VIEW IN BROWSER | SUBSCRIBE TUE, APR 13, 2021 EVENING BRIEF AS OF TUE, APR 13, 2021 • 04:44 ET DJIA 33677.27 -0.20% -68.13 S&P 500 4141.59 +0.33% +13.60 NASDAQ 13996.10 +1.05% +146.10   Most Active DOW NAME LAST CHG %CHG AAPL 134.43 +3.19 +2.43% INTC 65.22 -0.18 -0.28% MSFT 258.49 +2.58 +1.01% S&P 500 NAME LAST CHG %CHG AAPL 134.43 +3.19 +2.43% F 12.20 -0.18 -1.45% GE 13.44 -0.15 -1.10% NASDAQ NAME LAST CHG %CHG AAPL 134.43 +3.19 +2.43% TSLA 762.32 +60.34 +8.60% AMD 80.19 +1.61 +2.05%   EDITOR'S NOTE A widely watched inflation number came in slightly higher than expected on Tuesday but investors bet that it's not hot enough to spoil the economic recovery or trigger a reaction from the Federal Reserve.   The consumer price index, one of Wall Street's most-popular inflation gauges, rose 0.6% in March and increased 2.6% from the same period a year ago. Economists polled by Dow Jones were projecting the headline index to rise by 0.5% month over month and 2.5% year over year. The S&P 500 inched up to reach another record high, while the tech-heavy Nasdaq Composite outperformed with a 1% gain. Treasury yields fell after the inflation data.   "Today's CPI report reinforces that we're entering a period of strengthening, but not excessive, inflation, and we're witnessing the end to a long period of disinflation in many parts of the economy," Rick Rieder, BlackRock's chief investment officer of global fixed income, said in a note.   However, the potential impact of a halt in the rollout of the Johnson & Johnson Covid vaccine kept sentiment in check and caused a 68-point sell-off in the Dow Jones Industrial Average, which is comprised of stocks more tied to the economic reopening.   The U.S. Food and Drug Administration said it's recommending a pause in the J&J  vaccine after reported cases of blood clots. Acting FDA Commissioner Janet Woodcock said later Tuesday that she expects the pause to last "a matter of days." More than 6.8 million doses of the single-shot vaccine have been administered in the U.S. J&J shares fell 1%. Yun Li | CNBC Markets and Investing Reporter @YunLi626 TOP NEWS  S&P 500 closes at record, Nasdaq adds 1% as stocks shake off J&J vaccine halt, higher inflation FDA advises states to pause use of J&J Covid vaccine after rare blood-clotting issue affects 6 women, kills 1 Consumer prices rise more than expected, pushed by 9.1% jump in gasoline Coinbase is unlike any market debut Wall Street has ever seen Apple announces April 20 event where new iPads and more are expected States rush to replace J&J vaccine appointments after FDA recommends pause Morgan Stanley has high conviction these stocks will be higher over the next 15 to 60 days Gas tax is not being considered in Biden's infrastructure plan, White House says What the Coinbase listing means for the price of bitcoin and other cryptocurrencies Here's what investors should focus on when JPMorgan and Goldman kick off bank earnings Wednesday   TOP VIDEO Fauci addresses J&J vaccine pause — 'This is a very rare event'   CNBC PRO Here's what major analysts said about J&J, Moderna and other related stocks following the pause news   SPECIAL REPORTS Palantir could be gearing up for a big push higher. Here's how options traders are playing it 'When is the housing market going to crash?' is a red-hot search on Google – here's why   Unsubscribe Manage Newsletters Terms of Service Join the CNBC Panel Digital Products Feedback Privacy Policy   © 2021 CNBC LLC. All rights reserved. A property of NBCUniversal. 900 Sylvan Avenue, Englewood Cliffs, NJ 07632 Data is a real-time snapshot *Data is delayed at least 15 minutes. Global Business and Financial News, Stock Quotes and Market Data and Analysis. Data also provided by THOMSON REUTERS